ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Panel Recommends Peer Review “Fine Tuning” Changes Including Mandatory Service By All NIH Grantees

January 6, 1984

Healy’s “Save Bob” Campaign

January 6, 1995

In Brief: Goldsmith Named CEO of CancerCare

April 11, 2014

DeVita Defends CHP Awards, Says Program Has High Priority

September 5, 1980

ASCO Honors Eight With Special Awards

May 24, 2002

Report Doesn’t Quell Concerns About Duke Genomics Research, Biostatisticians Say

May 14, 2010